Comparative Pharmacology
Head-to-head clinical analysis: NAVSTEL versus VINCREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAVSTEL versus VINCREX.
NAVSTEL vs VINCREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NAVSTEL is a vascular disrupting agent that selectively targets and disrupts tumor vasculature by binding to tubulin at the colchicine-binding site, leading to microtubule depolymerization, cytoskeletal disruption, and subsequent endothelial cell apoptosis and necrosis in tumors.
Vinca alkaloid that binds to tubulin, inhibiting microtubule formation, thus disrupting mitotic spindle assembly and arresting cell division at metaphase.
400 mg orally once daily
1.5 mg/m2 IV push weekly, maximum single dose 2 mg.
None Documented
None Documented
Terminal half-life is 12 hours (range 10–14 h). With normal renal function, steady-state is reached after 2–3 days. Half-life extends to 24 hours in moderate renal impairment.
Terminal elimination half-life is 18-36 hours (mean 27 hours) in adults; prolonged in hepatic impairment (up to 60 hours) due to reduced clearance.
Renal excretion of unchanged drug accounts for 70% of clearance; biliary/fecal elimination accounts for 25%; 5% metabolized.
Primarily hepatic metabolism via CYP3A4, with biliary excretion of metabolites (65-75% in feces). Renal excretion accounts for 10-20% as unchanged drug and metabolites. Minimal (1-3%) in urine as parent compound.
Category C
Category C
Vinca Alkaloid Antineoplastic
Vinca Alkaloid Antineoplastic